Volume 6 Supplement 3

Metabolism, diet and disease

Open Access

Beyond insulin: rethinking cellular metabolism

  • Craig B Thompson1
BMC Proceedings20126(Suppl 3):O25

DOI: 10.1186/1753-6561-6-S3-O25

Published: 1 June 2012

The latest cancer therapeutics are almost all inhibitors of oncogenes or their downstream mediators. With the exception of imatinib, most such drugs have been disappointing in the clinic. In contrast, existing successful cancer drugs have a therapeutic index because they render the consequences of oncogene activation selectively toxic to the cancer cell. A renewed focus on this type of approach appears warranted and should be considered.

Authors’ Affiliations

Memorial Sloan-Kettering Cancer Center


© Thompson; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.